MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31, RNA has $292,360K in assets. $58,256K in debts. $267,849K in cash and cash equivalents.

Balance Sheets Overview

Current Ratio
1303.65%
Quick Ratio
1303.65%
Cash Ratio
1222.78%
Debt to Asset Ratio
19.93%
Unit: Thousand (K) dollars
Assets Breakdown
    • Cash and cash equivalents
    • Collaboration receivables
    • Property and equipment, net
    • Others
Liabilities Breakdown
    • Additional paid-in capital
    • Deferred revenue, net of current...
    • Retained earnings
    • Others

Balance Sheets
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Prepaid and other current assets
-101,598 90,181 67,416
Marketable securities
-1,314,352 1,525,678 939,237
Cash and cash equivalents
267,849 382,517 350,158 243,907
Collaboration receivables
15,000 ---
Prepaid assets
2,578 ---
Other current assets
138 ---
Total current assets
285,565 1,798,467 1,966,017 1,250,560
Restricted cash
415 2,797 2,798 2,798
Other assets
-82,175 91,042 90,806
Property and equipment, net
4,337 23,333 21,504 20,535
Right-of-use asset
2,043 51,278 52,848 4,227
Total assets
292,360 1,958,050 2,134,209 1,368,926
Accounts payable
807 12,403 9,626 3,914
Accrued liabilities
6,983 ---
Accrued expenses and other liabilities
-157,466 137,163 95,236
Accrued compensation
2,091 ---
Lease liabilities
2,680 3,938 3,967 3,925
Accrued compensation
---18,449
Deferred revenue, current portion
9,344 21,639 19,123 13,537
Total current liabilities
21,905 195,446 169,879 135,061
Lease liabilities, net of current portion
-45,313 45,999 1,210
Deferred revenue, net of current portion
36,351 28,691 32,066 39,991
Other long-term liabilities
0 ---
Total liabilities
58,256 269,450 247,944 176,262
Common stock, 0.001 par value 400,000,000 shares authorized and no shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively
16 15 15 12
Additional paid-in capital
-3,263,720 3,225,078 2,357,029
Accumulated other comprehensive income
-2,562 1,768 1,777
Additional paid-in capital
221,960 ---
Retained earnings
12,128 -1,577,697 -1,340,596 -1,166,154
Net investment from former parent
0 ---
Total stockholders' equity / former parent's deficit
234,104 1,688,600 1,886,265 1,192,664
Total liabilities and stockholders' equity / former parent's deficit
292,360 1,958,050 2,134,209 1,368,926
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Cash and cashequivalents$267,849K Collaboration receivables$15,000K Prepaid assets$2,578K Other current assets$138K Total current assets$285,565K Property and equipment,net$4,337K Right-of-use asset$2,043K Restricted cash$415K Total assets$292,360K Total liabilities andstockholders' equity / former...$292,360K Total stockholders'equity / former...$234,104K Total liabilities$58,256K Additional paid-in capital$221,960K Retained earnings$12,128K Common stock, 0.001 parvalue 400,000,000...$16K Deferred revenue, net ofcurrent portion$36,351K Total currentliabilities$21,905K Deferred revenue,current portion$9,344K Accrued liabilities$6,983K Lease liabilities$2,680K Accrued compensation$2,091K Accounts payable$807K

Avidity Biosciences, Inc. (RNA)

Avidity Biosciences, Inc. (RNA)